Working smarter: best practices for thermal modeling in cold chain packaging design

Smarter cold chain design starts with thermal modeling—learn best practices here.

Sept. 15, 2025

Lilly to give biotech startups access to AI tools

Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the pharma says can help young drugmakers while training its own models.

By Gwendolyn Wu • Sept. 9, 2025

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Novartis to gain heart drug in $1.4B deal for Tourmaline Bio

Tourmaline recently unveiled mid-stage trial data for its anti-inflammatory drug, which is ready for Novartis to advance into Phase 3 testing for heart disease.

By Delilah Alvarado • Sept. 9, 2025

Pfizer, BioNTech showcase new data supporting COVID booster

The companies said their updated shot spurred an increase in neutralizing antibodies against currently circulating strains, answering calls for more corroborating evidence.

By Delilah Alvarado • Sept. 8, 2025

Amgen to invest $600M in new US center; Sanofi drug for ITP approved

The new "science and innovation center" will be built at Amgen's headquarters in Thousand Oaks, California. Elsewhere, Wayrilz became the first BTK blocker cleared for immune thrombocytopenia.

By BioPharma Dive staff • Sept. 2, 2025

Amylyx drug comes up short; Sanofi names new CMO

AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building its first East Coast factory.

By BioPharma Dive staff • Aug. 27, 2025

Lilly to submit obesity pill after hitting goal in third late-stage trial

In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.

By Jonathan Gardner • Aug. 26, 2025

FDA cancels adcomm on Biohaven drug; Catalent lays off staff

Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff at a gene therapy facility.

By BioPharma Dive staff • Aug. 22, 2025

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen access to CAR-T treatment.

By Jonathan Gardner • Aug. 21, 2025

Lilly searching for new neuro chief as White set to retire

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly Neuroscience at the end of December.

By Ned Pagliarulo • Aug. 20, 2025

Kennedy’s mRNA cuts could set US science back, experts warn

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it harder to invest in companies advancing the technology.

By Delilah Alvarado • Aug. 18, 2025

The unexpected medication that could revolutionize the treatment of Alzheimer’s disease

A new wave of Alzheimer’s research suggests semaglutide, widely known for diabetes and weight loss, could also slow cognitive decline—two major trials aim to reveal the truth by 2025.

Aug. 18, 2025

Navigating the oncology patent cliff: Strategic imperatives for big pharma

Key cancer drugs lose exclusivity soon—who’s ready to withstand the oncology patent cliff?

By Andreas Dimakakos, Director of Scientific Insights, PhD, MBA, PMP ; and Elena Hilario Martinez, Customer Success Associate • Aug. 18, 2025

Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

By BioPharma Dive staff • Aug. 15, 2025

Merck KGaA ventures into new territory in the US

Miguel Fernández Alcalde, head of Merck KGaA’s U.S. arm, aims to “double down” on innovation. The company’s recent SpringWorks deal is just a start.

By Alexandra Pecci • Aug. 15, 2025

Pfizer looks to expand ADC use after positive bladder cancer data

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify for chemotherapy.

By Jonathan Gardner • Aug. 12, 2025

Bayer buys into KRAS cancer drug; Novartis immune therapy goes 3 for 3

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its study goal, while Biogen and Stoke began a key Phase 3 test.

By BioPharma Dive staff • Aug. 12, 2025

Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a multibillion-dollar deal that hadn’t yet paid dividends.

By Ben Fidler • Aug. 11, 2025

Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP

DTC isn’t converting to Rxs at the pharmacy. Learn how access may be key to your brand’s success.

Aug. 11, 2025

Inside AstraZeneca’s long-term strategy in lung cancer

Decades-long research has yielded a strong and growing franchise built around drugs for a genetic form of lung cancer.

By Michael Gibney • Aug. 8, 2025

Elevidys sales weaken; Neumora gets into obesity

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

By BioPharma Dive staff • Aug. 8, 2025

Lilly shares fall as obesity pill misses expectations in key trial

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts anticipated, leading to a selloff in shares that erased about $100 billion in market value. 

By Jonathan Gardner • Aug. 7, 2025

Novo pushes back against obesity drug compounders as competition intensifies

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.

By Jonathan Gardner • Aug. 6, 2025

Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled sales numbers for their chief drugs.

By BioPharma Dive staff • Aug. 6, 2025

US biotech needs government support to match China’s gains, Pfizer CEO says

“The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors in Aug. 5 comments on China’s rising competitiveness.

By Ben Fidler • Aug. 5, 2025